Delta-like canonical Notch ligand 3 is a novel therapeutic target for neuroendocrine tumors, having a huge field of pharmacologic development that has not been formally studied in non-neuroendocrine neoplasms. Here, DLL3 is linked to neuroendocrine neoplasm.